Takuya Fukui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takuya Fukui has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Akira Oshima
The Second Department of Internal Medicine, University of Toyama, Toyama 930-0194, Japan
1 shared publication - Hiroshi Ueno
University of Toyama
1 shared publication - Koichiro Kinugawa
The Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
1 shared publication - Makiko Nakamura
Second Department of Internal Medicine University of Toyama Toyama Japan
1 shared publication - Teruhiko Imamura
Second Department of Internal Medicine University of Toyama Toyama Japan
1 shared publication
Latest Publications
- Open Access
- 27 February 2022
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (3) , 71
Successful Management of Pheochromocytoma Crisis with Cardiogenic Shock by Percutaneous Left Ventricular Assist Device
Therapeutic strategy utilizing mechanical circulatory supports in patients with pheochromocytoma-related cardiogenic shock remains unestablished. We had a 51-year-old man with acute decompensated heart failure due to pheochromocytoma crisis. He received a percutaneous left ventricular assist device-supported alpha-blocker and intensive fluid infusion therapy, which ameliorated impaired end-organ dysfunction, maintaining hemodynamics and achieving cardiac recovery, followed by the successfully scheduled adrenalectomy. Early suspicion of pheochromocytoma and Impella-supported disease-specific medical management might be a promising bridge to surgery strategy.
- 27 February 2022
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (3) , 71
Open AccessSuccessful Management of Pheochromocytoma Crisis with Cardiogenic Shock by Percutaneous Left Ventricular Assist Device
Therapeutic strategy utilizing mechanical circulatory supports in patients with pheochromocytoma-related cardiogenic shock remains unestablished. We had a 51-year-old man with acute decompensated heart failure due to pheochromocytoma crisis. He received a percutaneous left ventricular assist device-supported alpha-blocker and intensive fluid infusion therapy, which ameliorated impaired end-organ dysfunction, maintaining hemodynamics and achieving cardiac recovery, followed by the successfully scheduled adrenalectomy. Early suspicion of pheochromocytoma and Impella-supported disease-specific medical management might be a promising bridge to surgery strategy.